Home LiteratureArticle Details
PMID: 30037853 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes.

Molecular cancer research : MCR ·Vol. 16 ·No. 12 ·2018-00-00 ·Pages 1889-1901

Ye IC, Fertig EJ, DiGiacomo JW, Considine M, Godet I, Gilkes DM

Abstract

Intratumoral hypoxia has been associated with invasion, metastasis, and treatment failure, prompting the need for a global characterization of the response to hypoxic conditions. The current study presents the results of a large-scale RNA sequencing (RNA-seq) effort, analyzing 31 breast cancer cell lines representative of breast cancer subtypes or normal mammary epithelial (NME) cells exposed to control tissue culture conditions (20% O2) or hypoxic conditions (1% O2). The results demonstrate that NME have a stronger response to hypoxia both in terms of number of genes induced by hypoxia as well as level of expression. A conserved 42-gene hypoxia signature shared across PAM50 subtypes and genes that are exclusively upregulated in Luminal A, Luminal B, and normal-like mammary epithelial cells is identified. The 42-gene expression signature is enriched in a subset of basal-like cell lines and tumors and differentiates survival among patients with basal-like tumors. Mechanistically, the hypoxia-inducible factors (HIF-1 and/or HIF-2) mediate the conserved hypoxic response. Also, four novel hypoxia-regulated and HIF-1-responsive genes were identified as part of the conserved signature. This dataset provides a novel resource to query transcriptional changes that occur in response to hypoxia and serves as a starting point for a clinical assay to aid in stratifying patients that would benefit from hypoxia-targeted therapies, some of which are currently in clinical trials. IMPLICATIONS: RNA-seq of 31 breast cancer cells exposed to control or hypoxic conditions reveals a conserved genomic signature that contains novel HIF-regulated genes and is prognostic for the survival of patients with triple-negative breast cancer.

MeSH Terms
Basic Helix-Loop-Helix Transcription Factors/genetics Breast Neoplasms/genetics,pathology Cell Hypoxia Cell Line, Tumor Cell Survival Female Gene Expression Profiling/methods Gene Expression Regulation, Neoplastic Gene Regulatory Networks Humans Hypoxia-Inducible Factor 1/genetics Prognosis Sequence Analysis, RNA/methods Survival Analysis
Chemicals
Basic Helix-Loop-Helix Transcription Factors Hypoxia-Inducible Factor 1 endothelial PAS domain-containing protein 1
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Ye I Chae
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Fertig Elana J
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
DiGiacomo Josh W
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. | Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.
Considine Michael
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Godet Inês
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. | Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.
Gilkes Daniele M
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. dgilkes1@jhu.edu. | Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.
References (56)
56 references, click to expand
  1. Tumour hypoxia causes DNA hypermethylation by reducing TET activity.
    Nature. 2016 Sep 1;537(7618):63-68 PMID: 27533040
  2. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
    Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 PMID: 7539918
  3. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
    Mol Cell. 2008 May 23;30(4):393-402 PMID: 18498744
  4. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.
    Genome Biol. 2014;15(12):550 PMID: 25516281
  5. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts.
    J Biol Chem. 2009 Jun 19;284(25):16767-75 PMID: 19386601
  6. Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A.
    Mol Cell Biol. 2012 Aug;32(15):3018-32 PMID: 22645302
  7. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  8. Integration of oxygen signaling at the consensus HRE.
    Sci STKE. 2005 Oct 18;2005(306):re12 PMID: 16234508
  9. Hypoxia Signaling Cascade for Erythropoietin Production in Hepatocytes.
    Mol Cell Biol. 2015 Aug;35(15):2658-72 PMID: 26012551
  10. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
    Cancer Res. 2007 Feb 1;67(3):854-5 PMID: 17283112
  11. Implications of Hypoxia in Breast Cancer Metastasis to Bone.
    Int J Mol Sci. 2016 Sep 30;17(10): PMID: 27706047
  12. Concordance among gene-expression-based predictors for breast cancer.
    N Engl J Med. 2006 Aug 10;355(6):560-9 PMID: 16899776
  13. Detection and characterization of tumor hypoxia using pO2 histography.
    Antioxid Redox Signal. 2007 Aug;9(8):1221-35 PMID: 17536958
  14. Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine.
    Cell. 2016 Jun 30;166(1):126-39 PMID: 27368101
  15. FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data.
    Tumour Biol. 2014 Mar;35(3):2607-17 PMID: 24318988
  16. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Cancer. 2003 Mar 15;97(6):1573-81 PMID: 12627523
  17. Hypoxia and cancer.
    J Mol Med (Berl). 2007 Dec;85(12):1301-7 PMID: 18026916
  18. Comprehensive molecular portraits of human breast tumours.
    Nature. 2012 Oct 4;490(7418):61-70 PMID: 23000897
  19. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
    Clin Cancer Res. 2013 Sep 1;19(17):4879-88 PMID: 23820108
  20. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
    Clin Cancer Res. 2015 Apr 1;21(7):1688-98 PMID: 25208879
  21. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  22. limma powers differential expression analyses for RNA-sequencing and microarray studies.
    Nucleic Acids Res. 2015 Apr 20;43(7):e47 PMID: 25605792
  23. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
    Lancet Oncol. 2005 Oct;6(10):757-64 PMID: 16198981
  24. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
    Clin Cancer Res. 2002 Jun;8(6):1831-7 PMID: 12060624
  25. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.
    Int J Radiat Biol. 2006 Oct;82(10):699-757 PMID: 17118889
  26. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
    Breast Cancer Res Treat. 2010 Oct;123(3):725-31 PMID: 20020197
  27. Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.
    Cell. 2016 Jan 14;164(1-2):293-309 PMID: 26771497
  28. Complex heatmaps reveal patterns and correlations in multidimensional genomic data.
    Bioinformatics. 2016 Sep 15;32(18):2847-9 PMID: 27207943
  29. Supervised risk predictor of breast cancer based on intrinsic subtypes.
    J Clin Oncol. 2009 Mar 10;27(8):1160-7 PMID: 19204204
  30. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences.
    F1000Res. 2015 Dec 30;4:1521 PMID: 26925227
  31. Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance.
    Biochim Biophys Acta. 2016 Mar;1863(3):379-381 PMID: 26721622
  32. The Molecular Signatures Database (MSigDB) hallmark gene set collection.
    Cell Syst. 2015 Dec 23;1(6):417-425 PMID: 26771021
  33. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    PLoS One. 2009 Jul 03;4(7):e6146 PMID: 19582160
  34. Transcriptional regulation by hypoxia-inducible factor 1 molecular mechanisms of oxygen homeostasis.
    Trends Cardiovasc Med. 1996 Jul;6(5):151-7 PMID: 21232289
  35. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy.
    Mol Cell Biol. 2007 Sep;27(17):6229-42 PMID: 17576813
  36. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.
    Oncologist. 2008;13 Suppl 3:21-6 PMID: 18458121
  37. Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.
    Nat Commun. 2016 Jun 06;7:11908 PMID: 27264733
  38. Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients.
    J Surg Oncol. 2017 Nov;116(6):706-715 PMID: 28570747
  39. Improved vectors and genome-wide libraries for CRISPR screening.
    Nat Methods. 2014 Aug;11(8):783-784 PMID: 25075903
  40. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.
    J Mol Med (Berl). 2012 Jul;90(7):803-15 PMID: 22231744
  41. Gene Expression Signatures as Biomarkers of Tumour Hypoxia.
    Clin Oncol (R Coll Radiol). 2015 Oct;27(10):547-60 PMID: 26282471
  42. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
    Cancer Cell. 2006 Dec;10(6):515-27 PMID: 17157791
  43. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.
    Blood. 2011 Jun 9;117(23):e207-17 PMID: 21447827
  44. Tumor Heterogeneity in Breast Cancer.
    Front Med (Lausanne). 2017 Dec 08;4:227 PMID: 29276709
  45. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
    Sci Signal. 2013 Apr 02;6(269):pl1 PMID: 23550210
  46. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.
    Cell Metab. 2006 Mar;3(3):177-85 PMID: 16517405
  47. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
    Br J Cancer. 2016 May 10;114(10):1071-7 PMID: 27070712
  48. Salmon provides fast and bias-aware quantification of transcript expression.
    Nat Methods. 2017 Apr;14(4):417-419 PMID: 28263959
  49. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.
    Genes Dev. 1997 Jan 1;11(1):72-82 PMID: 9000051
  50. Hypoxia Selectively Enhances Integrin α5β1 Receptor Expression in Breast Cancer to Promote Metastasis.
    Mol Cancer Res. 2017 Jun;15(6):723-734 PMID: 28213554
  51. Prognostic potential of the pre-therapeutic tumor oxygenation status.
    Adv Exp Med Biol. 2009;645:241-6 PMID: 19227477
  52. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
    J Clin Invest. 2011 Jul;121(7):2750-67 PMID: 21633166
  53. Hypoxia and adaptive landscapes in the evolution of carcinogenesis.
    Cancer Metastasis Rev. 2007 Jun;26(2):311-7 PMID: 17404691
  54. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
    Nature. 2012 Apr 18;486(7403):346-52 PMID: 22522925
  55. Comprehensive molecular biomarker identification in breast cancer brain metastases.
    J Transl Med. 2017 Dec 29;15(1):269 PMID: 29287594
  56. Collagen prolyl hydroxylases are essential for breast cancer metastasis.
    Cancer Res. 2013 Jun 1;73(11):3285-96 PMID: 23539444
Article Info
Journal
Molecular cancer research : MCR
Abbr.
Mol Cancer Res
ISSN
1557-3125
Published
2018-00-00
Epub
2018-00-23
Pages
1889-1901
Language
English
Region
United States
NLM ID
101150042
PMCID
PMC6279594
Subset
IM
Grants
NCI NIH HHS · U54 CA210173 · United States
NCI NIH HHS · U54 CA143868 · United States
NCI NIH HHS · P30 CA006973 · United States
NCI NIH HHS · K99 CA181352 · United States
NIH HHS · S10 OD016230 · United States
NCI NIH HHS · R00 CA181352 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com